Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Wolf-Karsten Hofmann, Arwin Mehralivand, Laurenz Steiner, Nanni Schmitt, Ahmed Jawhar, Cleo-Aron Weis, Stefanie Uhlig, Justine Danner, Vladimir Riabov, Ali Darwich, Qingyu Xu, Julia Obländer, Eva Altrock, Tobias Boch, Nadine Weimer, Florian Nolte, Antje Knaflic, Mohamad Jawhar, Alexander Streuer, Verena Haselmann, Daniel Nowak, Johann-Christoph Jann, Verena Nowak, Alexander Marx, Georgia Metzgeroth, Johanna Flach, Iris Palme
Publikováno v:
Leukemia
Preclinical research of myelodysplastic syndromes (MDSs) is hampered by a lack of feasible disease models. Previously, we have established a robust patient-derived xenograft (PDX) model for MDS. Here we demonstrate for the first time that this model
Autor:
Martina Rauner, Susann Winter, Uwe Platzbecker, Kristin Möbus, Lorenz C. Hofbauer, Heike Weidner, Michael Cross, Uta Oelschlägel, Nandini Asokan, Anna Mies, Martin Bornhäuser, Manja Wobus
Publikováno v:
Leukemia
The bone marrow microenvironment (BMME) plays a key role in the pathophysiology of myelodysplastic syndromes (MDS), clonal blood disorders affecting the differentiation, and maturation of hematopoietic stem and progenitor cells (HSPCs). In lower-risk
Autor:
Pierre Zachee, David M. Ross, Lynda Foltz, Atanas Radinoff, Francesco Mannelli, Evren Zor, Francisco Cervantes, Francesco Passamonti, Heinz Gisslinger, Geralyn Gilotti, Haifa Kathrin Al-Ali, Francesca Palandri, Alexandr Myasnikov, Alessandro M. Vannucchi, Islam Sadek, Ranjan Tiwari, Norio Komatsu
Publikováno v:
Leukemia
Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) evaluated the efficacy and safety of a novel ruxolitinib dosing strategy with
Autor:
Martina Pontone, Fabrizio Ensoli, Enea Gino Di Domenico, Elena Papa, Atelda Romano, Valentina Laquintana, Caterina Viggiani, Livia Ronchetti, Ornella Di Bella, Aldo Morrone, Gennaro Ciliberto, Paolo Falcucci, Daniela Renzi, Svitlana Gumenyuk, Iole Cordone, Simona di Martino, Laura Conti, Francesca Palombi, Diana Giannarelli, Branka Vujovic, Andrea Mengarelli, Francesco Pisani, Antonia La Malfa, Francesco Marchesi, Chiara Mandoj, Fulvia Pimpinelli
Publikováno v:
Leukemia
Autor:
Courtney D. DiNardo, Lewis R. Silverman, Charles Cai, Claudia D. Baldus, Isabelle Genvresse, Eleni Lagkadinou, Neil Palmisiano, Walter Fiedler, Alice S. Mims, Michael Jeffers, Markus Wagner, Ioannis Mantzaris, Alexander E. Perl, Gary Wilkinson, Bingyan Wu, Christine Rentzsch, Eunice S. Wang, Timothy S. Pardee, Sebastian Schwind, Stefan Kaulfuss, Michael Heuser, Alwin Krämer
Publikováno v:
Leukemia
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses rang
Autor:
John M. Ashton, Phil Rock, Jason R. Myers, Myra Coppage, Jane L. Liesveld, Naxin Guo, Mitra Azadniv, Laura M. Calvi, Helene R. McMurray, Michael W. Becker
Publikováno v:
Leukemia
Bone marrow mesenchymal stromal cells (MSCs) constitute one of the important components of the hematopoietic microenvironmental niche. In vivo studies have shown that depletion of marrow MSCs resulted in reduction of hematopoietic stem cell content,
Autor:
Philip George, Yvette Hoade, Sahra Ali, Simon Watt, Varun Mehra, Catherine Cargo, Fergus Jack, Paul Evans, Tiziana Fanelli, William J. Tapper, Alastair Whiteway, Gabriela Sciuccati, Iwo Pieniak, Jamie Cavenagh, Emma Das-Gupta, Andres Virchis, Nicole Naumann, Kavita Patel, Rowena Thomas-Dewing, Patrick Thornton, Kris Zegocki, Louise Wallis, Charlotte Grimley, Gonzalo Carreño-Tarragona, Peter Forsyth, Andreas Reiter, Nicholas C.P. Cross, Laura Munro, Kaljit Bhuller, Andrew S Duncombe, Andrew Chase, Barbara J. Bain, Mohamad Jawhar, Johannes Lübke, Ali Rismani, Sonja Burgstaller
Publikováno v:
Leukemia
Cross, N C P, Hoade, Y, Tapper, W J, Carreno-tarragona, G, Fanelli, T, Jawhar, M, Naumann, N, Pieniak, I, Lübke, J, Ali, S, Bhuller, K, Burgstaller, S, Cargo, C, Cavenagh, J, Duncombe, A S, Das-gupta, E, Evans, P, Forsyth, P, George, P, Grimley, C, Jack, F, Munro, L, Mehra, V, Patel, K, Rismani, A, Sciuccati, G, Thomas-dewing, R, Thornton, P, Virchis, A, Watt, S, Wallis, L, Whiteway, A, Zegocki, K, Bain, B J, Reiter, A & Chase, A 2018, ' Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia ', Leukemia . https://doi.org/10.1038/s41375-018-0342-3
Cross, N C P, Hoade, Y, Tapper, W J, Carreno-tarragona, G, Fanelli, T, Jawhar, M, Naumann, N, Pieniak, I, Lübke, J, Ali, S, Bhuller, K, Burgstaller, S, Cargo, C, Cavenagh, J, Duncombe, A S, Das-gupta, E, Evans, P, Forsyth, P, George, P, Grimley, C, Jack, F, Munro, L, Mehra, V, Patel, K, Rismani, A, Sciuccati, G, Thomas-dewing, R, Thornton, P, Virchis, A, Watt, S, Wallis, L, Whiteway, A, Zegocki, K, Bain, B J, Reiter, A & Chase, A 2018, ' Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia ', Leukemia . https://doi.org/10.1038/s41375-018-0342-3
Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a diagnostic challenge in many cases. We identified STAT5B N642H, an established oncogenic mutation, in 27/1715 (1.6%) cases referr
Autor:
Paul Kerbs, Philipp A. Greif, Wolfgang Hiddemann, Michel Sadelain, Marion Subklewe, Tobias Herold, Fabiana Perna, Samuel H. Berman, Stephanie Schneider, Sascha Haubner, Christina Krupka, Thomas Köhnke, Christian Augsberger, Felix S. Lichtenegger, X. Liu, Karsten Spiekermann, Christian Schmidt, Klaus H. Metzeler, Frauke M. Schnorfeil
Publikováno v:
Leukemia
Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from minor clones. We hypothesize that
Autor:
David Jucker, V. Pillonel, Andreas Zettl, A. Bodmer, Stefan Dirnhofer, Charlotte K.Y. Ng, Darius Juskevicius, Alexandar Tzankov
Publikováno v:
Leukemia
Nodal marginal zone lymphoma (NMZL) is a rare small B-cell lymphoma lacking disease-defining phenotype and precise diagnostic markers. To better understand the mutational landscape of NMZL, particularly in comparison to other nodal small B-cell lymph